

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF EDWIN CLARK, ET AL
FOR: BIOMARKERS AND METHODS FOR DETERMINING SENSITIVITY TO EPIDERMAL GROWTH
FACTOR RECEPTOR MODULATORS
APPLICATION NO: 10/585261 APPLICATION DATE: 01/07/2005
ART UNIT: 1642 EXAMINER:
CONFIRMATION NO: 3933 USPTO CUSTOMER NO: 23914

TRANSMITTED VIA EFS-WEB

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §1.56, Applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

These references were cited in a PCT International Search Report. Copies of these references and the search report are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Statement under 37 C.F.R. §1.97(e)(1)


I, the undersigned attorney, hereby state that each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.

Statement under 37 C.F.R. §1.704(d)

I, the undersigned attorney, hereby state that each item of information contained in this information disclosure statement was cited in any communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000


Paul D. Golan
Attorney for Applicants
Reg. No. 42,591
Phone: 609-252-4091
Date: 9/25/07